CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies

Trial Profile

CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Dec 2017

At a glance

  • Drugs Anti-CD19 CAR-transduced T cells (Primary) ; Carmustine; Cytarabine; Etoposide; Interleukin-2; Melphalan; Rituximab
  • Indications Follicular lymphoma; Lymphoid leukaemia; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Dec 2017 According to a Ziopharm Oncology media release, results from this trial were presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition.
    • 10 Jun 2017 Biomarkers information updated
    • 04 Aug 2016 According to a ZIOPHARM Oncology media release, data from this study has been published in the Journal of Clinical Investigation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top